Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: Possible alternative drug therapies (Q70243849)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6338686%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

title

Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: possible alternative drug therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6338686%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: Possible alternative drug therapies (English)

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(83)80200-8

2 October 2023

1 reference

coronary artery disease

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(83)80200-8

2 October 2023

author name string

R. P. Ames

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6338686

2 October 2023

language of work or name

English

0 references

publication date

1 February 1983

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6338686%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

24 February 1983

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6338686

full work available at URL

2 October 2023

https://api.elsevier.com/content/article/PII:S0002914983802008?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(83)80200-8

https://api.elsevier.com/content/article/PII:S0002914983802008?httpAccept=text/plain

2 October 2023

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(83)80200-8

American Journal of Cardiology

2 October 2023

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6338686%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6338686%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6338686%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

page(s)

632-638

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6338686%20AND%20SRC:MED&resulttype=core&format=json

Antihypertensive treatment and the course of established cerebral vascular disease

9 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Treatment of mild hypertension: a five year controlled drug trial. The Oslo study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Multivariate prediction of coronary heart disease during 8.5 year follow-up in the western collaborative group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Improvement of glucose tolerance and lowering of glycohemoglobin and serum lipid concentrations after discontinuation of antihypertensive drug therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Sounding board. Should mild hypertension be treated?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

FURTHER OBSERVATIONS CONCERNING THE HYPERGLYCEMIC ACTIVITY OF BENZOTHIADIAZINES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

THIAZIDE- AND PHTHALIMIDINE-INDUCED HYPERGLYCEMIA IN HYPERTENSIVE PATIENTS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Nonenzymatic Glucosylation of Serum Proteins in Diabetes Mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Glucosylation of human collagen in aging and diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Coronary heart-disease after treatment of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

A long-term prevention study with oxprenolol in coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Metabolic consequences of atenolol and propranolol in treatment of essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Effect of propranolol and prazosin on blood lipids. The Oslo Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Effect of prazosin on serum lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2883%2980200-8

Long-term Effect of Sotalol on Plasma Lipids

7 January 2021

30

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(83)80200-8

Plasma lipid and lipoprotein changes in hypertensive patients treated with propranolol and prazosin

2 October 2023

35

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(83)80200-8

Open assessment of the effect of prazosin on plasma lipids

2 October 2023

36

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(83)80200-8

2 October 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6338686%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

1 reference